This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.– Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of...
AACR 2023 presentation highlights noteworthy diagnostic performance potential using cell-free microbial DNA in diagnosing early-stage lung cancer April 19, 2023. San Diego, CA—Highlighting that cancer is no longer considered a sterile disease, Greg Sepich-Poore,...
Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifyingthe “infinite potential” of using microbiome markers to diagnose cancer.March 29, 2023. SAN DIEGO, Calif.–Based on an independent team of expert’srigorous evaluation of a broad...
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy created to detect lung carcinomas in its earliest stages January 10, 2023. SAN DIEGO, Calif.– Micronoma, the first biotech company developing early cancer detection with a microbiome-driven...
December 14, 2022. SAN DIEGO, Calif.– Micronoma, the first biotech company offering early cancer detection using a microbiome-driven liquid biopsy platform, today announced that Sandrine Miller-Montgomery, Ph.D., Pharm.D., CEO and Co-founder of Micronoma will...
An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma provides the most comprehensive characterization of fungi in cancer to date, discovering synergistic interactions with bacteria and furthering the role of mycobiome as an...
